USA Manufacturing Site Expansion – Abingdon Health plc

York, UK and Madison, WI, USA, 27 May 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that its US subsidiary, Abingdon Health USA, Inc., has entered into a Business Development Tax Credit Agreement with the Wisconsin Economic Development Corporation (“WEDC”). WEDC serves as the state’s agency for economic development, fostering job growth and business expansion.

Under the agreement, Abingdon Health USA, Inc. has been certified as eligible to earn up to US$370,000 in performance-based Wisconsin tax credits over a three-year period commencing 1 January 2026. The credits comprise up to US$320,000 linked to the creation of new full-time roles and up to US$50,000 linked to qualifying capital investment at the Group’s facilities in Wisconsin over this period.  The amount of credits the Company will receive is contingent on the number of jobs created and amount of capital invested.

This award reflects the continued growth of the Group’s US operations and supports the ongoing expansion of its facilities in Madison, Wisconsin, which serve as Abingdon Health’s North American base for development, manufacturing and commercial activities.

John W. Miller, Secretary and CEO of WEDC, said “Abingdon’s decision to locate in Wisconsin and continue to grow here reflects the strength of our state’s leadership in the field of biohealth and biotechnology, our outstanding research institutions, and our highly trained workforce.  WEDC is proud to partner with Abingdon as they open this next chapter.”

Chris Yates, President of Abingdon Health USA Inc, said: “We are grateful for this award from the Wisconsin Economic Development Corporation, which serves as a welcome endorsement of our commitment and investment in Wisconsin and our positioning in the US market. These tax credits will support our expansion at University Research Park in Madison, including the creation of additional skilled roles as Abingdon Health USA continues to grow to meet customer demand across the United States.”

Any shareholders wishing to keep up to date with Abingdon Health news, please email [email protected]

Enquiries

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Hand, Executive Chairman

Via Walbrook PR

Tom Hayes, CFO

Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)

 Tel: +44 (0)20 7220 0500

Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance)

Nigel Birks (Life Science Specialist Sales)

Walbrook PR (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

About Abingdon Health

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.  

The Group’s CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory strategy support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.

Abingdon’s regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.  The Company’s subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

Abingdon Health’s brochures outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.

Source link

Switzerland-Based Novartis Breaks Ground on Radioligand Therapy Site in Denton » Dallas Innovates

Novartis breaks ground on its Denton radioligand therapy site. [Photo: Novartis]

Swiss global pharmaceutical giant Novartis recently broke ground on its new radioligand therapy (RLT) manufacturing site in Denton, part of its broader $23 billion investment in U.S. manufacturing and research.

When completed in 2028, the company’s first Texas‑based manufacturing facility will bring RLT medications closer to patients across the southern United States, becoming the fifth RLT site nationwide, Novartis said.

Novartis CEO Vas Narasimhan said radioligand therapy “is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale.”

“Breaking ground in Denton further strengthens our U.S. supply chain and helps ensure patients can receive these highly personalized treatments when and where they need them,” Narasimhan added in a statement.

The 46,000-square foot facility aims to boost Novartis’ position as the first company to deliver RLT at scale, creating the network capacity needed as these therapies extend into earlier stages of treatment and a broader range of cancers. Announced earlier this year, the Denton facility is expected to create new U.S.-based Novartis jobs in bioengineering, advanced manufacturing, quality, and operations, supporting economic growth in Denton and surrounding communities, the company said. 

Swiss ambassador, U.S. Department of Commerce official took part in groundbreaking 

Taking part in the groundbreaking in Denton were U.S. Under Secretary of Commerce for Industry and Security Jeffrey Kessler; Swiss Ambassador to the U.S. Ralf Heckner; Texas State Senator Brent Hagenbuch; Texas State Representative Andy Hopper; and Denton Mayor Gerard Hudspeth. They joined Novartis leadership, employees, and community partners to celebrate the start of construction.

“I’m pleased to welcome Novartis to Denton as their newest manufacturing location for their cancer therapies,” Texas State Senator Brent Hagenbuch said in a statement. “Their decision establishes a strong partnership and reflects the unique opportunity Denton provides to a well-educated workforce, and the unique access the new plant location will provide to the vibrant North Texas economy and rapidly growing state population.”

Producing medications for U.S. patients in the U.S.

The Texas facility strengthens the Novartis coast-to-coast RLT manufacturing network, with existing US sites in New Jersey, Indiana and California, and another new site being added in Florida. Together, the facilities make up the largest U.S. RLT manufacturing network, further bolstering the company’s longstanding track record of enabling over 99% of doses to be administered on the planned day of treatment.

Each dose of RLT is custom-made and requires precise coordination, the company said, making manufacturing reliability and proximity to treatment centers key factors in providing timely treatment.

At the groundbreaking, Kessler said the Trump Administration “is delivering historic wins for the American people—lowering drug prices, revitalizing manufacturing, creating jobs, and attracting massive new investments. Novartis’s groundbreaking today is the latest example of the Administration’s successful policies at work.

In April 2025, Novartis said it was designating $23 billion over five years to grow its U.S. research and manufacturing footprint. Seven new and three expanded facilities across the country are already under construction—part of the company’s goal of manufacturing all key medicines for U.S. patients in the U.S, supporting supply resilience and dependable delivery of medicines.

Don’t miss what’s next. Subscribe to Dallas Innovates.

Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.

Source link

Samsung Biologics establishes first U.S. manufacturing base with acquisition of GSK site – Chemical Engineering

April 3, 2026 | By Mary Bailey

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States.

The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales. With this addition, Samsung Biologics’ total global manufacturing capacity increases to 845,000 liters.

Samsung Biologics will continue supplying the products previously manufactured at the site to GSK under the terms of the agreement, and the site will transition to serve additional contract manufacturing needs. Samsung Biologics also plans further investments to expand the site’s capacity and upgrade technologies, reinforcing its long-term commitment to advancing a more resilient global supply chain and improving patient access to critical medicines.

“This represents a meaningful step in expanding our U.S. manufacturing footprint. The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family,” said John Rim, President and CEO of Samsung Biologics. “The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network. As a CDMO, our mission is to help our partners bring important therapies to patients worldwide, and this site will play a pivotal role in that mission while ensuring continuity and upholding the high standards our clients expect.”

The completion follows the previously announced agreement to acquire the facility on December 22, 2025.

Source link